Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is N/A as of 2026-10-06T21:05:41.536Z.
Calculation as of: 2026-10-06T21:05:41.536Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fdfad12185ff1a6c55ef1236bc2340ccae7aa6e4dec3824b1e7761c8ffaeec30
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2022-06-30.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
N/A
PB RATIO AVG TTM
N/A
PB RATIO AVG 3Y
N/A
PB RATIO AVG 5Y
N/A
PB RATIO AVG 10Y
N/A
PB RATIO AVG 15Y
N/A
PB RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$2.11B
PB Ratio
15.33
TTM Avg
11.92
3Y Avg
10.21
5Y Avg
7.96
Market Cap
$2.02B
PB Ratio
N/A
TTM Avg
68.48
3Y Avg
35.35
5Y Avg
46.14
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alvotech (ALVO) | $2.08B | N/A | N/A | N/A | N/A |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | 3.66 | 5.15 | 4.02 | 4.79 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | 2.89 | 3.81 | 3.48 | 4.00 |
| Vericel Corporation (VCEL)vs › | $2.05B | 5.54 | 5.70 | 7.80 | 8.18 |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | 15.33 | 11.92 | 10.21 | 7.96 |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | 5.18 | 5.47 | 6.24 | 5.42 |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 1.84 | 1.83 | 2.09 | 2.24 |
| Progyny, Inc. (PGNY)vs › | $2.03B | 4.48 | 4.22 | 4.79 | 8.25 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | N/A | 68.48 | 35.35 | 46.14 |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | 8.73 | 9.41 | 7.19 | 4.79 |
P/B Ratio
N/A
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PB RATIO |
|---|---|
| 2022-06-30 | 8.77 |
| 2022-06-29 | 9.03 |
| 2022-06-28 | 9.59 |
| 2022-06-27 | 9.78 |
| 2022-06-24 | 9.44 |
| 2022-06-23 | 9.61 |
| 2022-06-21 | 1.36 |
| 2022-06-17 | 1.32 |
| 2022-06-16 | 1.53 |
